Deerfield Management Company, L.P. (Series C) Acadia Pharmaceuticals Inc Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 35,154 shares of ACAD stock, worth $589,532. This represents 0.01% of its overall portfolio holdings.
Number of Shares
35,154Holding current value
$589,532% of portfolio
0.01%Shares
2 transactions
Others Institutions Holding ACAD
# of Institutions
281Shares Held
156MCall Options Held
901KPut Options Held
314K-
Baker Bros. Advisors LP New York, NY42.9MShares$719 Million7.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.8MShares$232 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY13.7MShares$230 Million3.36% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$202 Million0.0% of portfolio
-
State Street Corp Boston, MA5.97MShares$100 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $2.71B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...